8-K: Arbutus Biopharma Announces 2025 Corporate Update and Financial Outlook, Plans Phase 2b Trial

Arbutus Biopharma is advancing its hepatitis B program with a planned Phase 2b trial for imdusiran, reporting positive clinical data and a strong financial position.

Summary

• Arbutus Biopharma has announced its 2025 corporate objectives and provided a financial update.
• The company plans to initiate a Phase 2b clinical trial for its RNAi therapeutic, imdusiran, in the first half of 2025.
• This trial will combine imdusiran with interferon and nucleos(t)ide analogue (NA) therapy.
• The Phase 2b trial is expected to enroll approximately 170 HBeAg-negative cHBV patients with baseline HBsAg less than 1000 IU/mL.
• Arbutus reported a 50% functional cure rate in a subset of patients in its Phase 2a trial using imdusiran, interferon and NA therapy.
• The company also presented data on its oral PD-L1 inhibitor, AB-101, which is currently in a Phase 1a/1b clinical trial.
• Arbutus had approximately $123 million in cash, cash equivalents, and investments as of December 31, 2024.
• The company anticipates a net cash burn of $47 to $50 million in 2025, compared to approximately $65 million in 2024.
• Arbutus believes its current cash and anticipated milestones will fund operations through the first quarter of 2028.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the strong clinical results, solid financial position, and clear development plans. The company's progress in achieving a functional cure for HBV and its reduced cash burn are encouraging for investors.

Positives

• The company has a strong cash position of $123 million as of December 31, 2024.
• The planned Phase 2b trial for imdusiran is fully funded.
• The company anticipates a significant reduction in cash burn in 2025.
• The company has achieved a meaningful functional cure rate in a Phase 2a trial.
• The company has a strategic partnership with Qilu Pharmaceutical in Greater China.
• The company is advancing its oral PD-L1 inhibitor, AB-101, in a Phase 1a/1b clinical trial.

Negatives

• The financial information provided is preliminary and unaudited.
• The company is involved in ongoing patent litigation, which carries inherent uncertainties.
• The success of clinical trials is not guaranteed and may be subject to delays or unexpected results.
• The company's future success depends on regulatory approvals and market acceptance of its products.

Risks

• Clinical trials may be more costly or take longer to complete than anticipated.
• The company may not receive necessary regulatory approvals for its products.
• Economic and market conditions may worsen, impacting the company's financial position.
• The company may need to utilize its at-the-market program based on changes in its business.
• The company's plans to reduce net cash burn may not materially extend the cash runway.
• There are risks related to the sufficiency of the company's cash resources and its ability to obtain adequate financing in the future.

Future Outlook

Arbutus anticipates a reduced cash burn in 2025 and believes its current cash and anticipated milestones will fund operations through the first quarter of 2028, including the Phase 2b imdusiran trial. The company also expects to continue its patent litigation efforts.

Management Comments

• Michael J. McElhaugh, Interim President and Chief Executive Officer of Arbutus, stated that the company enters 2025 with solid financial footing and strong momentum in achieving its mission of developing a functional cure for cHBV.
• Management believes that imdusiran is differentiated from other RNAi therapeutics in development for HBV.

Industry Context

This announcement is significant in the context of the ongoing efforts to find a functional cure for chronic hepatitis B, a disease affecting over 250 million people worldwide. Arbutus's progress with imdusiran and AB-101 positions them as a key player in this field, competing with other companies developing novel HBV therapies.

Comparison to Industry Standards

• The 50% functional cure rate in a subset of patients in Arbutus's Phase 2a trial is a notable result compared to the less than 10% functional cure rate seen with current treatments.
• Companies like Gilead Sciences and Vir Biotechnology are also developing HBV therapies, but Arbutus's approach with RNAi and a PD-L1 inhibitor offers a unique combination strategy.
• The planned Phase 2b trial for imdusiran is a significant step forward, comparable to other companies advancing their HBV candidates through clinical development.
• Arbutus's cash runway through Q1 2028 is a strong position compared to other biotech companies that may need to raise capital more frequently.

Legal Proceedings

• Arbutus is involved in ongoing patent litigation against Moderna and Pfizer/BioNTech regarding the use of its LNP technology in their COVID-19 vaccines.
• The claim construction hearing for the lawsuit against Pfizer/BioNTech occurred on December 18, 2024, with a ruling expected in the first half of 2025.
• The trial date for the lawsuit against Moderna is scheduled for September 24, 2025, subject to court availability.

Stakeholder Impact

• Shareholders are likely to react positively to the strong clinical data and financial outlook.
• Employees may be motivated by the company's progress and clear development plans.
• Patients with chronic hepatitis B may benefit from the development of new treatment options.
• The company's strategic partnership with Qilu Pharmaceutical may benefit both companies.

Next Steps

• Initiate a Phase 2b clinical trial for imdusiran in the first half of 2025.
• Report functional cure data from the IM-PROVE II Phase 2a trial in the first half of 2025.
• Report preliminary data from Cohort 3A of the AB-101-001 trial in the first half of 2025.
• Receive a court ruling on the claim construction for the Pfizer/BioNTech lawsuit in the first half of 2025.
• Continue expert reports and depositions in the Moderna lawsuit, with a trial date scheduled for September 24, 2025.

Key Dates

Keywords

Hepatitis B, cHBV, Imdusiran, RNAi, AB-101, PD-L1 inhibitor, Clinical Trial, Functional Cure, LNP, Intellectual Property, Cash Burn, Biopharmaceutical